Published in the prestigious journal Brain on Wednesday, July 20, 2016, groundbreaking research from INSERM (France's National Institute of Health and Medical Research) offers real hope for multiple sclerosis (MS) patients. Scientists identified an antibody-drug, Glunomab, that dramatically slowed or even halted MS progression in mouse models, igniting optimism for this debilitating neurological condition affecting 1 in 1,000 people.
Multiple sclerosis is an autoimmune disorder where the immune system mistakenly attacks the body's own cells, particularly myelin—the protective sheath around nerve fibers. Symptoms vary widely, including balance issues, vision problems, numbness, and electric shock-like sensations. As the leading cause of non-traumatic severe disability in young adults (average onset at age 30), MS impacts an estimated 80,000 people in France alone—one in 1,000—with women affected more than men. Until now, no treatment has successfully stopped its progression.
MS triggers inflammatory reactions that destroy myelin in patches, disrupting nerve signal transmission and causing symptoms. The immune system views myelin as foreign, slowing or blocking impulses. During remission, inflammation subsides and myelin partially regenerates, easing symptoms. However, repeated or chronic demyelination permanently damages neurons, resulting in lasting disability.
Glunomab, the newly discovered antibody, shows remarkable potential to curb MS advancement. As INSERM researcher Fabien Docagne, a study co-author, explains: "This drug demonstrated significant efficacy in a mouse model mimicking MS. Treated mice improved, disease progression was prevented, and they avoided hind-limb paralysis. No side effects were observed. Given its promise, we hope it advances to human treatment."
While promising, Glunomab remains untested in humans, with trials still experimental. A patent is filed, but funding shortages persist; the team seeks industrial partners to accelerate development. As ARSEP Vice-President Pierre-Olivier Couraud notes: "From such results to market approval typically takes over a decade."
Nonetheless, this INSERM discovery shines a vital light of hope for those battling multiple sclerosis.
